Reuters -- Norwegian drug company Photocure ASA's Hexvix failed to meet one of two main goals in a study comparing the proposed imaging agent with a standard test for detecting bladder cancer, U.S. reviewers said on Tuesday.
Reuters -- Norwegian drug company Photocure ASA's Hexvix failed to meet one of two main goals in a study comparing the proposed imaging agent with a standard test for detecting bladder cancer, U.S. reviewers said on Tuesday.
